Breaking news

Bank Of England Governor Dismisses Government Rift Amid Revolut License Delays


Bank Of England Defends Government Relations

London – In a recent discussion with CNBC, Bank of England Governor Andrew Bailey dismissed speculation of any discord between the central bank and the U.K. government over delays in fintech giant Revolut’s progression toward full banking status. Bailey confirmed that interactions with Finance Minister Rachel Reeves have remained constructive, refuting reports of a falling out.

Revolut’s Journey Toward Full Banking Authorization

Revolut’s lengthy application process, which began in 2021, culminated in the granting of a restricted banking license in July 2024 by the Prudential Regulation Authority. Despite this milestone, the digital bank remains confined to a transitional ‘mobilization’ phase, limiting customer deposits to £50,000— a stark contrast to the extensive deposits handled by established high-street institutions like Barclays, HSBC, and Santander.

Regulatory Engagement And Market Implications

Although Revolut’s U.K. customers are currently served through its e-money unit and lack the direct protection of the Financial Services Compensation Scheme, the Prudential Regulation Authority is actively engaged in facilitating the digital bank’s transition. Bailey emphasized that there is no inherent trade-off between maintaining financial stability and fostering economic growth, and he expressed an openness to regulatory adjustments to support innovation in the fintech sector.

Industry Scrutiny And Government Response

Delays in granting full banking licenses to fintech firms have sparked criticism from the U.K. tech industry, which argues that more robust support is needed for the country to remain competitive on the global stage. The governor’s remarks underscore a commitment to balance rigorous oversight with a willingness to adapt policies that encourage a thriving digital financial landscape.


EU Records €220.5 Billion Pharmaceutical Trade Surplus In 2025

The European Union secured a historic trade surplus in medicinal and pharmaceutical products in 2025, according to a report from Eurostat. Export figures reached €366.2 billion while imports totaled €145.7 billion, leading to a surplus of €220.5 billion.

Robust Growth In Exports And Imports

Exports increased by 16.0% from €315.7 billion in 2024. Imports rose by 21.0% from €120.4 billion over the same period. The data show continued expansion in trade volumes across the sector.

Leading National Performances

Ireland recorded the highest exports to non-EU countries at €93.8 billion. Germany and Belgium followed with €67.9 billion and €38.5 billion, respectively. Italy led imports at €27.5 billion, with Belgium and Germany also recording significant volumes.

Global Trade Partnerships

The United States was the largest destination for EU exports, accounting for 43.8% or €160.6 billion. Switzerland followed with 16.3% (€59.7 billion), while the United Kingdom accounted for 5.6% (€20.6 billion). On the import side, the United States supplied 41.2% of total imports (€60.1 billion), followed by Switzerland at 28.4% (€41.4 billion) and China at 9.0% (€13.1 billion).

Aretilaw firm
The Future Forbes Realty Global Properties
eCredo
Uol

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter